BIBW 2992 (Afatinib) in Head & Neck Cancer
NCT00514943
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
124
Enrollment
INDUSTRY
Sponsor class
Conditions
Head and Neck Neoplasms
Carcinoma, Squamous Cell
Interventions
DRUG:
BIBW 2992
DRUG:
Cetuximab
Sponsor
Boehringer Ingelheim